| 000 | 01530 a2200421 4500 | ||
|---|---|---|---|
| 005 | 20250514050653.0 | ||
| 264 | 0 | _c20030421 | |
| 008 | 200304s 0 0 eng d | ||
| 022 | _a1520-9156 | ||
| 024 | 7 |
_a10.1089/152091502760306616 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMoskowitz, David W | |
| 245 | 0 | 0 |
_aFrom pharmacogenomics to improved patient outcomes: angiotensin I-converting enzyme as an example. _h[electronic resource] |
| 260 |
_bDiabetes technology & therapeutics _c2002 |
||
| 300 |
_a519-32 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article | ||
| 650 | 0 | 4 |
_aAngiotensin-Converting Enzyme Inhibitors _xtherapeutic use |
| 650 | 0 | 4 | _aBlack People |
| 650 | 0 | 4 |
_aDiabetic Nephropathies _xdrug therapy |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGenomics |
| 650 | 0 | 4 | _aGenotype |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypertension _xdrug therapy |
| 650 | 0 | 4 |
_aKidney Failure, Chronic _xetiology |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMissouri |
| 650 | 0 | 4 |
_aPeptidyl-Dipeptidase A _xgenetics |
| 650 | 0 | 4 |
_aPolycystic Kidney, Autosomal Dominant _xdrug therapy |
| 650 | 0 | 4 | _aPolymorphism, Genetic |
| 650 | 0 | 4 |
_aPulmonary Disease, Chronic Obstructive _xgenetics |
| 650 | 0 | 4 | _aSex Characteristics |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 | _aWhite People |
| 650 | 0 | 4 | _aBlack or African American |
| 773 | 0 |
_tDiabetes technology & therapeutics _gvol. 4 _gno. 4 _gp. 519-32 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1089/152091502760306616 _zAvailable from publisher's website |
| 999 |
_c12205490 _d12205490 |
||